First Time Loading...

Orchid Pharma Ltd
NSE:ORCHPHARMA

Watchlist Manager
Orchid Pharma Ltd Logo
Orchid Pharma Ltd
NSE:ORCHPHARMA
Watchlist
Price: 997.1 INR -0.56% Market Closed
Updated: Jun 3, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Orchid Pharma Ltd

Revenue
8.1B INR
Cost of Revenue
-4.8B INR
Gross Profit
3.4B INR
Operating Expenses
-2.1B INR
Operating Income
1.3B INR
Other Expenses
-99.3m INR
Net Income
1.2B INR

Margins Comparison
Orchid Pharma Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
IN
Orchid Pharma Ltd
NSE:ORCHPHARMA
50.6B INR
41%
16%
15%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
790B USD
80%
32%
17%
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK
85%
45%
37%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
355.6B USD
70%
28%
45%
US
Merck & Co Inc
NYSE:MRK
325.2B USD
75%
10%
4%
UK
AstraZeneca PLC
LSE:AZN
191.4B GBP
82%
18%
13%
CH
Roche Holding AG
SIX:ROG
185B CHF
73%
32%
20%
CH
Novartis AG
SIX:NOVN
181.4B CHF
74%
28%
30%
US
Pfizer Inc
NYSE:PFE
165.7B USD
70%
19%
-1%
Country IN
Market Cap 50.6B INR
Gross Margin
41%
Operating Margin
16%
Net Margin
15%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 790B USD
Gross Margin
80%
Operating Margin
32%
Net Margin
17%
Country DK
Market Cap 4.1T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
37%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country US
Market Cap 355.6B USD
Gross Margin
70%
Operating Margin
28%
Net Margin
45%
Country US
Market Cap 325.2B USD
Gross Margin
75%
Operating Margin
10%
Net Margin
4%
Country UK
Market Cap 191.4B GBP
Gross Margin
82%
Operating Margin
18%
Net Margin
13%
Country CH
Market Cap 185B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country CH
Market Cap 181.4B CHF
Gross Margin
74%
Operating Margin
28%
Net Margin
30%
Country US
Market Cap 165.7B USD
Gross Margin
70%
Operating Margin
19%
Net Margin
-1%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Orchid Pharma Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
IN
Orchid Pharma Ltd
NSE:ORCHPHARMA
50.6B INR
14%
9%
12%
12%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
790B USD
51%
10%
28%
17%
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK
100%
33%
87%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
355.6B USD
52%
21%
19%
14%
US
Merck & Co Inc
NYSE:MRK
325.2B USD
5%
2%
7%
4%
UK
AstraZeneca PLC
LSE:AZN
191.4B GBP
17%
6%
12%
10%
CH
Roche Holding AG
SIX:ROG
185B CHF
40%
13%
29%
22%
CH
Novartis AG
SIX:NOVN
181.4B CHF
38%
17%
22%
17%
US
Pfizer Inc
NYSE:PFE
165.7B USD
0%
0%
6%
1%
Country IN
Market Cap 50.6B INR
ROE
14%
ROA
9%
ROCE
12%
ROIC
12%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 790B USD
ROE
51%
ROA
10%
ROCE
28%
ROIC
17%
Country DK
Market Cap 4.1T DKK
ROE
100%
ROA
33%
ROCE
87%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country US
Market Cap 355.6B USD
ROE
52%
ROA
21%
ROCE
19%
ROIC
14%
Country US
Market Cap 325.2B USD
ROE
5%
ROA
2%
ROCE
7%
ROIC
4%
Country UK
Market Cap 191.4B GBP
ROE
17%
ROA
6%
ROCE
12%
ROIC
10%
Country CH
Market Cap 185B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country CH
Market Cap 181.4B CHF
ROE
38%
ROA
17%
ROCE
22%
ROIC
17%
Country US
Market Cap 165.7B USD
ROE
0%
ROA
0%
ROCE
6%
ROIC
1%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More